Xiclofen: US FDA label indications
US FDA labelNot medical advice
Label details
- Brand name
- Xiclofen
- Generic name
- Diclofenac Sodium, Methyl Salicylate
- Manufacturer
- ASCLEMED USA INC.
- Route
- Cutaneous
- Product type
- Human Prescription Drug
- Substance
- Diclofenac Sodium
Indications and usage (label excerpt)
1. INDICATIONS & USAGE Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more.
Warnings (label excerpt)
5. WARNINGS, PRECAUTIONS & ADVERSE REACTIONS 5.1 Risk of Serious Cardiovascular and Gastrointestinal Events Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause an increased risk of serious cardiovascular (CV) thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. NSAIDs, including diclofenac, can lead to new onset of hypertension, or worsening of preexisting hypertension, either of which may contribute to the increased incidence of CV events. To minimize the potential risk for an adverse CV event in NSAID-treated patients, use the lowest effective dose for the shortest duration possible. Avoid the use of diclofenac sodium external in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If diclofenac sodium external is used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Avoid using NSAID…
Excerpts are shortened. Read the full label, and ask a pharmacist or prescriber about any medicine. Full label on DailyMed(opens in a new tab) For products sold in Canada, see the Health Canada Drug Product Database(opens in a new tab).
Trials whose interventions mention this drug
Canadian trials first. A match on the drug name does not mean the trial studied this specific product.
4 trials, recruiting first
| Phase | Countries | ||||
|---|---|---|---|---|---|
| The Incidence of Thoracic Disc Herniation in Patients Presenting With Chronic Upper Back Pain NCT05313997 | Completed | Turkey (Türkiye) | Kocaeli University | 2022-05-24 | |
| Bonipar for Acute and Chronic Musculoskeletal Pain NCT03471507 | Completed | Phase 2 | United States | Winston Parris, MD | 2020-12-15 |
| Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment NCT03362216 | Completed | Not applicable | Peking University People's Hospital | 2009-04-07 | |
| Long-term Outcomes of Breast Cancer Patients After Wound Infiltration Analgesia NCT05829707 | Completed | Phase 4 | Osijek University Hospital | 2009-01-05 |
Source: openFDA drug label (US FDA), snapshot October 2026. Not a Health Canada Product Monograph.